Pitavastatin-d4 (hemicalcium)

• UNSPSC Description:

  Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

• Target Antigen:

  Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR); Isotope-Labeled Compounds; Mitophagy

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis;Autophagy;Metabolic Enzyme/Protease;Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Metabolic Disease; Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4C([2H])([2H])C4([2H])[2H].[Ca+2].[1/2]

• Molecular Weight:

  444.52

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7(1):5410.|[3]Kajinami K, et al. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003 Fall;21(3):199-215.|[4]Mukhtar RY, et al. Pitavastatin. Int J Clin Pract. 2005 Feb;59(2):239-52.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported